Evidence map›Paper›PMID 37317989›Full record

ArticleVeterinary medicine and science2023

Metabolism of ropinirole is mediated by several canine CYP enzymes.

Tuomas Tervahauta, Päivi Uutela, Mikko Koskinen

Open access · goldAbstract read
In one paragraph

Article in Veterinary medicine and science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tuomas TervahautaOrion Corporation, Orion Pharma, Espoo, Finland.
Päivi UutelaOrion Corporation, Orion Pharma, Espoo, Finland.
Mikko KoskinenOrion Corporation, Orion Pharma, Espoo, Finland.ORCID 0000-0003-2033-051X
Orion Corporation (Finland) · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRopinirole has been shown to provoke vomiting in dogs by activating the dopamine D2-like receptors in the chemoreceptor trigger zone. In humans, ropinirole is metabolized primarily by CYP1A2. Corresponding dog CYP1A2 is known to be a polymorphic enzyme which can cause variation in pharmacokinetics of compounds metabolised via this enzyme.

objectivesThe aim of this study was to understand metabolic clearance of ropinirole in dogs, the enzymes involved in ropinirole metabolism and specially to estimate whether the clearance can be sensitive towards the polymorphism of canine CYP1A2.

methodsMetabolism of ropinirole was studied in dog hepatocytes and specific recombinant canine CYP isoforms. Metabolite identification and metabolite formation were evaluated using LC-mass spectrometry.

resultsRopinirole was moderately stable in dog hepatocytes with Cl

conclusionsAlthough human metabolism of ropinirole is mainly mediated through CYP1A2, the current study shows that several canine CYP isoforms are able to contribute to the clearance of ropinirole in dogs. This is expected to reduce a possible impact of canine CYP1A2 polymorphism on ropinirole pharmacokinetics.

Indexed as

Cytochrome P-450 CYP1A1Cytochrome P-450 CYP1A2AnimalsCytochrome P-450 Enzyme SystemDogsHumansIndolesMicrosomes, LiverCytochrome P-450 CYP1A1Cytochrome P-450 CYP1A2Cytochrome P-450 Enzyme SystemIndolesropiniroleCYPdogin vitroropinirole

Identifiers

PMID37317989
PMCPMC10357277
OpenAlexW4380730902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.